Assessment of dysphagia and its associations in patients with secondary progressive multiple sclerosis

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Multiple sclerosis and related disorders Pub Date : 2025-02-01 DOI:10.1016/j.msard.2024.106254

Majid Hamidi, Nasim Rezaeimanesh, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi

引用次数: 0

Abstract

In this cross-sectional study in patients with secondary progressive multiple sclerosis receiving anti-CD20 monoclonal antibodies, we assessed complaint of dysphagia and evaluated their association with sex, age, disease duration, disability severity, and disease-modifying therapies (DMTs). The validated Persian version of Dysphagia in Multiple Sclerosis (DYMUS) questionnaire was used. A total of 66 patients were included. The median DYMUS score was 1.0 [interquartile range: 0.0-2.3] and 40 (60.6%) had positive DYMUS. Only DMT showed a significant association with DYMUS score, with patients receiving reituximab exhibiting higher scores (mean estimated difference: 0.96 (±0.39), p = 0.014). Grouping patients into positive and negative DYMUS scores, no significant associations were observed (p > 0.05).

查看原文本刊更多论文

继发性进展性多发性硬化症患者的吞咽困难及其相关性评估。

在这项接受抗cd20单克隆抗体治疗的继发性进行性多发性硬化症患者的横断面研究中，我们评估了吞咽困难的主诉，并评估了其与性别、年龄、疾病持续时间、残疾严重程度和疾病改善治疗（dmt）的关系。使用波斯语版的多发性硬化症吞咽困难（DYMUS）问卷。共纳入66例患者。DYMUS评分中位数为1.0[四分位数范围：0.0-2.3]，DYMUS阳性40例（60.6%）。只有DMT与DYMUS评分有显著相关性，接受瑞妥昔单抗的患者评分更高（平均估计差值：0.96（±0.39），p = 0.014）。将患者分为DYMUS阳性和阴性，无显著相关性（p < 0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.